Registry of Patients Living with Type 1 Diabetes
NCT03720197
Recruiting
A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc. Participation to the... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/24/2025
Locations: Alberta Diabetes Institute, Edmonton, Alberta +6 locations
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree
NCT06851546
Recruiting
The purpose of this study to optimize Selective Laser Trabeculoplasty (SLT) application when used in the management of open angle glaucoma (OAG)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota +1 locations
Conditions: Open Angle Glaucoma
Register for Updates
Safety and Effectiveness of Automated Insulin Delivery (AID) Systems in Physically Active Adults with Type 1 Diabetes
NCT05626725
Recruiting
Despite recent medical and technological advances, optimal glycemic control (time in range; TIR) and prevention of hypoglycemia remain significant challenges for people living with type 1 diabetes (T1DM). Automated insulin delivery systems (AIDs) combine an insulin pump coupled via an algorithm with a continuous glucose monitor (CGM), allowing constant adjustment of insulin doses according to blood glucose levels. Despite the significant improvement in blood glucose parameters and quality of lif... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec
Conditions: Type 1 Diabetes
Register for Updates
Glycemic Control and Osteohealth in Adults Living with Type 1 Diabetes
NCT06158503
Recruiting
Bone damage is frequently observed in type 1 diabetes, and hyperglycemia is associated with an increased risk of fracture. This pilot study in 25 people living with type 1 diabetes aims to determine whether the introduction of an automated insulin delivery (AID) system improves bone markers through rapide optimization of glycemic control. Measurements will be taken before the start of AID, 2 months and 4 months afterwards.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/24/2025
Locations: CHUM, Montréal, Quebec +1 locations
Conditions: Type 1 Diabetes
Register for Updates
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
NCT06285409
Recruiting
This study will investigate the effects of drugs called "uterotonics" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery. An uncontracted uterine state is called "uterine atony", which can lead to an excessive amount of post-delivery bleeding. Carbetocin is an uterotonic drug that works well to prevent post-delivery bleeding. In some cases, carbetocin is not enough to contract the uterus, and ongoing b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
02/24/2025
Locations: Mount Sinai Hospital, Toronto, Ontario
Conditions: Postpartum Hemorrhage
Register for Updates
Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living with Type 1 Diabetes
NCT06683391
Recruiting
The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of lif... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Institut de recherches cliniques de Montréal, Montreal, Quebec +1 locations
Conditions: Type 1 Diabetes
Register for Updates
Dose Efficacy in Adhesive Capsulitis
NCT06848374
Recruiting
The purpose of this study is to find out if the treatment of adhesive capsulitis with 40 mg of methylprednisolone in combination with a hydrodilatation is comparable to 80 mg of methylprednisolone for pain reduction, improving shoulder mobility, and reducing side effects. Researchers will enroll 40 people in this study which is taking place solely at the Toronto Rehabilitation Institute, University Avenue. This study should take approximately 12 months to complete and the results should be know... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2025
Locations: Toronto Rehabilitation Institution, Toronto, Ontario
Conditions: Adhesive Capsulitis of the Shoulder
Register for Updates
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
NCT02674100
Recruiting
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +15 locations
Conditions: Pancreatic Cancer
Register for Updates
Psilocybin for Treatment-Resistant Depression in Autism with Pre-Post Brain and Cognitive Measurement to Understand Mechanisms
NCT06731621
Recruiting
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Treatment Resistant Depression, Autism Spectrum Disorder
Register for Updates
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
NCT04935619
Recruiting
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Cannabis Use, Major Depressive Disorder, Cognitive Impairment
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Birmingham, Alabama +75 locations
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM)
NCT06065215
Recruiting
Bronchopulmonary dysplasia (BPD) is a common, major complication of premature birth, associated with developmental and health consequences that continue into adulthood. Prediction of who will have these problems is challenging using traditional definitions of disease. It is believed that underdevelopment and injury occur in both lung tissue and the blood vessels in the lungs, with a sophisticated interplay between them that contributes to lung disease seen in prematurity. New magnetic resonance... Read More
Gender:
ALL
Ages:
Between 35 weeks and 21 months
Trial Updated:
02/21/2025
Locations: The Children's Hospital of Eastern Ontario, Ottawa, Ontario +3 locations
Conditions: Lung Function, BPD - Bronchopulmonary Dysplasia
Register for Updates